Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.

摘要: A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment Cancer Lung Cooperative Group (EORTC) to receive one two cisplatin (Platinol)-based chemotherapy regimens: Paclitaxel (Taxol) 175 mg/m2 given 3-hour infusion followed 80 on day 1; Or 1, teniposide (Vumon) 100 days 3, 5. Cycles repeated every 3 weeks. Preliminary analysis results this phase III trial shows that hematologic toxicity was decidedly more severe in group treated cisplatin/teniposide than those paclitaxel/cisplatin. Of 264 evaluable so far, responses have been observed 47% paclitaxel 29% teniposide. However, extramural radiologic response evaluation is still under way, these figures are expected change somewhat. It appears clear paclitaxel-based therapy affords a benefit terms toxicity, but survival premature any definite conclusions await final analysis.